Frequently Asked Questions
BiondVax FAQ
When was BiondVax founded, and what has the company achieved?
BiondVax was founded in 2003 by Dr. Ron Babecoff, based on technology developed by Copaxone co-developer Professor Ruth Arnon of the Weizmann Institute in Israel. The company successfully executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate, which did not meet the trial’s clinical endpoints. The company has built and operates a GMP biologics manufacturing facility for biopharmaceutical products. Following the 2021 appointment of Amir Reichman as CEO, BiondVax signed exclusive license and related collaboration agreements with the Max Planck Institute for Multidisciplinary Science and University Medical Center Gottingen, Germany for development of a pipeline of nanosized antibody (NanoAb) therapies.
What does the company do?
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases and related illnesses, beginning with an innovative nanosized antibody (NanoAb) pipeline.
Where are the company's headquarters located?
The company’s headquarters are in Israel, on the 2nd floor of the Jerusalem BioPark Building on the Hadassah Ein Kerem campus. The company’s state-of-the-art GMP manufacturing facility houses its laboratories, production facilities and offices.
How many employees does the company have?
BiondVax's team of about 27 includes scientists, technicians, researchers, and administrative staff.
Who is BiondVax’s outside legal counsel?
BiondVax legal counsel is Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co. Their website is https://www.gkh-law.com/ and they can be contacted by phone at +972-3-607-4444.
Who are BiondVax’s independent accountants?
BiondVax works with Ernst & Young in Israel and can be contacted on +972 3 623 2525.
What is BiondVax’s board diversity?
Financial FAQ
What is BiondVax’s fiscal year?
The fiscal year ends on December 31 of each calendar year. First Quarter ends: March 31 Second Quarter ends: June 30 Third Quarter ends: September 30 Fourth Quarter ends: December 31.
When does the company announce quarterly financial results?
Financial results are typically announced just prior to 3 months following the close of the quarter.
What forms does BiondVax file with the regulatory authorities?
From May 2015, as BiondVax is a foreign filer for US SEC purposes. While it is not required to file a 10K or 10Q, BiondVax typically files its quarterly results and any important information under 6K filings with the SEC and files full year audited financial statements under a 20F filing. Prior to May 2015, Biondvax’s filings are all in Hebrew, filed with the Tel Aviv Stock Exchange.
Stock FAQ
When did BiondVax go public?
In June 2007, BiondVax started trading on the Tel-Aviv Stock Exchange (TASE), and voluntarily delisted from TASE in January, 2018. In May 2015, the company listed American Depository Shares (ADS) on Nasdaq. One ADS represents 40 ordinary shares of BiondVax. In addition, the company had warrants outstanding which were issued together with its Nasdaq offering; the warrants expired by May 15, 2020.
Where is BiondVax’s stock traded?
BiondVax’s shares are listed under a Sponsored - Level III ADR program on Nasdaq in the United States. BiondVax voluntarily delisted from TASE in January, 2018.
What is BiondVax’s ticker?
BiondVax’s American Depository Shares (ADS) trade on Nasdaq under the ticker BVXV.
How many shares does BiondVax have outstanding?
As of February, 2021, BiondVax has approximately 14.3 million American Depository Shares outstanding. There is a 40:1 ratio between ordinary shares formerly traded on the Tel Aviv Stock Exchange (TASE) and American Depository Shares.
What is the Company's stocks ISIN & CUSIP numbers?
Prior to voluntarily delisting from the Tel Aviv Stock Exchange (TASE) in January 2018, BiondVax’s TASE listed shares traded under ISIN IL0011052045. BiondVax’s Nasdaq ADS trade under CUSIP 09073Q105 and warrants traded under CUSIP 09073Q113.
Who manages the Company’s ADS program?
BNY Mellon manages the ADS program and can be contacted at Adrdesk@bnymellon.com.